Recommendations for the clinical and laboratory diagnosis of VITT against COVID‐19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. (20th May 2021)

• Record Type: Journal Article
• Authors: Nazy, Ishac; Sachs, Ulrich J.; Arnold, Donald M.; McKenzie, Steven E.; Choi, Phil; Althaus, Karina; Ahlen, Maria Therese; Sharma, Ruchika; Grace, Rachael F.; Bakchoul, Tamam
• Is Part Of: Journal of thrombosis and haemostasis. Volume 19:Number 6(2021)
• Page Start: 1585
• Page End: 1588
• Publication Date: 2021-05-20
• Subjects: AstraZeneca ChadOx1 nCov‐19 vaccine -- COVID‐19 -- platelet activation -- thrombocytopenia -- thrombosis; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.15341
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract: Vaccine administration is under way worldwide to combat the current COVID‐19 pandemic. The newly developed vaccines are highly effective with minimal adverse effects. Recently, the AstraZeneca ChadOx1 nCov‐19 vaccine has raised public alarm with concerns regarding the rare, but serious, development of thrombotic events, now known as vaccine‐induced immune thrombotic thrombocytopenia (VITT). These thrombotic events appear similar to heparin‐induced thrombocytopenia, both clinically and pathologically. In this manuscript, the ISTH SSC Subcommittee on Platelet Immunology outlines guidelines on how to recognize, diagnose and manage patients with VITT.